Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
Nishigaki T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hara H, Sugase T, Otsuru T, Saito Y, Tsujii S, Nomura T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Eguchi H, Yamasaki M, Mori M, Doki Y, Naka T. Nishigaki T, et al. Among authors: sugase t. Br J Cancer. 2020 Apr;122(9):1333-1341. doi: 10.1038/s41416-020-0781-2. Epub 2020 Mar 10. Br J Cancer. 2020. PMID: 32152502 Free PMC article.
Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.
Sugase T, Takahashi T, Serada S, Nakatsuka R, Fujimoto M, Ohkawara T, Hara H, Nishigaki T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Kishimoto T, Mori M, Doki Y, Naka T. Sugase T, et al. Int J Cancer. 2017 Jun 1;140(11):2608-2621. doi: 10.1002/ijc.30666. Epub 2017 Mar 10. Int J Cancer. 2017. PMID: 28233302 Free article.
Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma.
Harada E, Serada S, Fujimoto M, Takahashi Y, Takahashi T, Hara H, Nakatsuka R, Sugase T, Nishigaki T, Saito Y, Hiramatsu K, Nojima S, Mitsuo R, Ohkawara T, Morii E, Mori M, Doki Y, Kaneda Y, Naka T. Harada E, et al. Among authors: sugase t. Oncotarget. 2017 Apr 11;8(15):24741-24752. doi: 10.18632/oncotarget.15799. Oncotarget. 2017. PMID: 28445969 Free PMC article.
SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Nishida T, Hirota S, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanasaki K, Kishimoto T, Mori M, Doki Y, Naka T. Sugase T, et al. Gastric Cancer. 2018 Nov;21(6):968-976. doi: 10.1007/s10120-018-0822-1. Epub 2018 Apr 5. Gastric Cancer. 2018. PMID: 29623544
Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1.
Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, Matsuzaki S, Ueda Y, Yoshino K, Ohkawara T, Fujimoto M, Kishimoto T, Kimura T, Naka T. Nakagawa S, et al. Among authors: sugase t. Mol Cancer Ther. 2018 Sep;17(9):1941-1950. doi: 10.1158/1535-7163.MCT-17-0822. Epub 2018 Jun 11. Mol Cancer Ther. 2018. PMID: 29891489
98 results